Hyaluronic acid grafting mitigates calcification of glutaraldehyde-fixed bovine pericardium.
Pathologic calcification is the leading cause of the clinical failure of glutaraldehyde-fixed bovine pericardium used in bioprosthetic valves. A novel surface modification of glutaraldehyde fixed bovine pericardium was carried out with high molecular weight hyaluronic acid (HA). HA was chemically modified with adipic dihydrazide (ADH) to introduce hydrazide functional groups onto the HA backbone. Glutaraldehyde-fixed bovine pericardium (GFBP) was modified by grafting this HA to the free aldehyde groups on the tissue via the hydrazide groups. Following a 2-week subcutaneous implantation in osteopontin (OPN)-null mice, the calcification of HA-modified bovine pericardium was drastically reduced (by 84.5%) compared to positive controls (tissue without HA-modification) (p = 0.005). The calcification-mitigating effect of HA surface modification was also confirmed by microscopic analysis of explanted tissue stained with Alizarin Red S for calcium.
Ohri
Rachit
R
Department of Bioengineering, University of Washington, Box 351720, Bagley Hall, #479, Seattle, Washington 98195.
Hahn
Sei K
SK
Hoffman
Allan S
AS
Stayton
Patrick S
PS
Giachelli
Cecilia M
CM
D000818:Animals; D001672:Biocompatible Materials / Q000737:chemistry; D001705:Bioprosthesis / Q000009:adverse effects; D002114:Calcinosis / Q000517:prevention & control*; D002417:Cattle; D005260:Female; D005404:Fixatives; D005976:Glutaral; D006350:Heart Valve Prosthesis / Q000009:adverse effects; D006801:Humans; D006820:Hyaluronic Acid / Q000737:chemistry; D008422:Materials Testing; D051379:Mice; D018345:Mice, Knockout; D053495:Osteopontin; D010496:Pericardium / Q000637:transplantation*; D012795:Sialoglycoproteins / Q000172:deficiency / Q000235:genetics
D001672:Biocompatible Materials; D005404:Fixatives; C506895:SPP1 protein, human; D012795:Sialoglycoproteins; C506896:Spp1 protein, mouse; D053495:Osteopontin; D006820:Hyaluronic Acid; D005976:Glutaral